

30th November 2006, Melbourne, Australia.

RESULTS OF THE ANNUAL GENERAL MEETING

Held at 2.00pm on Thursday 30 November 2005

Melbourne, VIC – Benitec Limited (ASX: BLT) announces that all resolutions at the Annual General Meeting, held today, were unanimously passed by a show of hands of shareholders present and the following information is provided in accordance with Section 251AA(2) of the Corporations Act and ASX Listing Rule 3.12.2.

There were a total of 19,668,064 proxies received. The valid proxy votes received by Benitec for the resolutions were:

2. Re-election of Mr Peter Francis

Votes where the proxy was directed to vote 'for' the resolution	18,632,337
Votes where the proxy was directed to vote 'against' the resolution	Nil
Votes where the proxy may exercise a discretion how to vote	1,035,727
In addition, the number of votes where the proxy was directed to abstain from voting on the resolution was	Nil

3. Re-election of Dr Michael Dalling

Votes where the proxy was directed to vote 'for' the resolution	18,623,670
Votes where the proxy was directed to vote 'against' the resolution	8,667
Votes where the proxy may exercise a discretion how to vote	1,035,727
In addition, the number of votes where the proxy was directed to abstain from voting on the resolution was	Nil

4. Re-election of Dr Ken Reed

Votes where the proxy was directed to vote 'for' the resolution	18,632,337
Votes where the proxy was directed to vote 'against' the resolution	Nil
Votes where the proxy may exercise a discretion how to vote	1,035,727
In addition, the number of votes where the proxy was directed to abstain from voting on the resolution was	Nil

5. Ratification of Share Option Issue – Cappello Capital Corporation

Votes where the proxy was directed to vote 'for' the resolution	17,682,948
Votes where the proxy was directed to vote 'against' the resolution	949,389
Votes where the proxy may exercise a discretion how to vote	1,035,727
In addition, the number of votes where the proxy was directed to abstain from voting on the resolution was	Nil

6. Ratification of Share Issue – Promega Corporation

Votes where the proxy was directed to vote 'for' the resolution	18,508,837
Votes where the proxy was directed to vote 'against' the resolution	123,500
Votes where the proxy may exercise a discretion how to vote	1,035,727
In addition, the number of votes where the proxy was directed to abstain from voting on the resolution was	Nil

7. Re-Approval of Employee Share Option Plan

Votes where the proxy was directed to vote 'for' the resolution	18,548,948
Votes where the proxy was directed to vote 'against' the resolution	83,389
Votes where the proxy may exercise a discretion how to vote	1,035,727
In addition, the number of votes where the proxy was directed to abstain from voting on the resolution was	Nil

8. Adoption of Remuneration Report

Votes where the proxy was directed to vote 'for' the resolution	16,508,926
Votes where the proxy was directed to vote 'against' the resolution	13,667
Votes where the proxy may exercise a discretion how to vote	3,145,471
In addition, the number of votes where the proxy was directed to abstain from voting on the resolution was	Nil

In accordance with Listing Rule 3.13.3 Benitec wishes to advise that the Corporate Presentation address by Ms Sue MacLeman, CEO, was lodged with the market prior to the meeting.



Paul McMahon
Company Secretary
30 November 2006

About Benitec

Benitec is an Australian biotechnology company focused on developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. The company's main therapeutic program is in the area of Human Immunodeficiency Virus (HIV). Benitec's RNA-based HIV therapeutic, co-developed with the Center for Biomedicine & Genetics at the City of Hope in Los Angeles, California, will enter Phase I clinical trials in 2006. For additional information, please visit www.benitec.com.

Forward-looking Statements

This press release contains forward-looking statements that reflect the Company's current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially

from those projected herein and depend on a number of factors including the success of the Company's research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

Sue MacLeman
Chief Executive Officer
+61 437211200

Rudi Michelson
Monsoon Communications
+61 411402737